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KIR3DL2/CD158k/p140 is a three domain killer cell immunoglobulin-like receptor incorpo-
rating cytoplasmic immunoreceptor tyrosine inhibitory motifs, expressed as a disulphide-
bonded dimer. KIR3DL2 is a framework genewithin the KIR locus and is highly polymorphic,
with 62 allelic variants possibly coding for protein reported. KIR3DL2 binds to HLA-A3 and -
A11 in a peptide-dependent fashion and to B27 free heavy chain forms. In addition, KIR3DL2
can also function as an innate immune receptor for delivery of CpG DNA toTLR9 in NK cells.
The increased levels of expression of KIR3DL2 compared with other KIR expressed byT cell
subsets in healthy individuals suggest it may function as a default KIR receptor. KIR3DL2-
expressing natural killer (NK) cells and IL17 secreting CD4 T cells have been implicated
in the pathogenesis of ankylosing spondylitis. Moreover, KIR3DL2 expression delineates
circulating and cutaneous lymphoma T cells in Sézary’s syndrome. Here we discuss how
the unique molecular attributes of KIR3DL2 impact on its function on NK and T cells and
how this may relate to its role in disease.
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INTRODUCTION
KIR3DL2 has the CD designation CD158k. KIR3DL2 has been
variously referred to as NKAT4, NKAT4a, NKAT4b, and cl-
5. The extracellular ligand-binding regions of the killer cell
immunoglobulin-like receptor (KIR) family of which KIR3DL2 is
a member are arranged in domains with an immunoglobulin-fold
like (Ig) structure. KIR are classiﬁed based upon how many extra-
cellular C2-type immunoglobulin-like domains they have (2D for
two domains, 3D for three domains) and by the length of their
cytoplasmic domain (L for long-tailed receptors and S for short
ones; Marsh et al., 2003).
GENE ORGANIZATION AND ALLELIC VARIATION
The gene for KIR3DL2 is a framework gene within the KIR gene
locus. KIR3DL2 nucleotide sequences are the longest of all KIR
genes spanning 16,256 bp in full genomic sequences and cod-
ing for a 1,368 bp cDNA (reviewed in the IPD-KIR database:
http://www.ebi.ac.uk/ipd/kir). The genomic sequence comprises
many putative regulatory elements, some of which are unique
to the KIR3DL2 gene, suggesting transcriptional regulation dis-
tinct from other KIR genes. These include putative binding sites
for RUNX, c-myc, p53, and NFκB transcription factors (Trows-
dale et al., 2001; Cichocki et al., 2009). In addition there are also
KIR3DL2 allelic variants in non-coding DNA which may have
effects on gene transcription.
KIR3DL2 PROTEIN STRUCTURE
KIR3DL2, is expressed as a protein with signal peptide, sequen-
tial D0, D1, and D2 immunoglobulin-like domains, stem and
cytoplasmic tail regions. Similar to other three domain KIRs, the
KIR3DL2 gene incorporates nine exons. Exons 1–2 encode for sig-
nal peptide. The D0, D1, and D2 immunoglobulin-like domains,
stem, transmembrane, and cytoplasmic tail regions are encoded
by exons 3–5, 6, 7, and 8–9, respectively (Colonna and Samaridis,
1995). The D0, D1, D2 domains, stem, and transmembrane
regions of KIR3DL2 proteins are 96, 102, 98, 24, and 20 amino
acids in length, respectively. The cytoplasmic tail of KIR3DL2 is
the longest of all KIR3D proteins incorporating 96 amino acids
and contains two regulatory immunoreceptor tyrosine inhibitory
motifs (ITIMs).
KIR3DL2*001 is unique among KIR in being expressed as a
140 kDa dimer (p140, Pende et al., 1996). There are two unpaired
cysteines in the stem region at positions 302 and 336 which are not
in the D0, D1, and D2 Ig-like domains and which may be involved
in disulphide-bonded dimerization.
Eighty four allelic variants of KIR3DL2 have been reported
of which 62 encode for potential proteins. The relative expres-
sion levels of these different alleles is unknown. Alleles differ
by amino acid substitutions. 48 of the allelic variants differ
in amino acid sequence in the D0 domain or in the region
between the D0 and D1 domains. Whilst the D0 domains of
KIR3DL1 and KIR3DS1 are similar, the sequence of KIR3DL2
differs signiﬁcantly in this region. This strongly suggests that the
KIR3DL2 D0 domain has an important role to play in binding to
ligand.
REGULATION OF KIR3DL2 EXPRESSION
A mean of 24.3% [interquartile range (IQR): 18.7–27.7] natural
killer (NK) cells express KIR3DL2 in healthy individuals (Chan
et al., 2005). These levels are similar to the proportions of NK cells
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in healthy individuals that express other KIR for which antibodies
are available such as KIR3DL1.
KIR3DL2 is expressed on a higher proportion of CD4 and
CD8 T cells than other KIR (Chan et al., 2005). We have shown
that a mean of 9% (IQR: 4.6–13.7) peripheral blood CD8 T
cells and 5% CD4 T cells (IQR: 1.8–6) express KIR3DL2 com-
pared to 0.5 and 1% of CD4 and CD8 T expressing other KIR,
respectively. This suggests that KIR3DL2 expression may be less
tightly controlled than other KIR. KIR3DL2 expression is enriched
on memory CD45RO+CD28−CCR7−CD62L− T cells (Chan
et al., 2005). A higher proportion of CD28−CD4 T cells express
KIR3DL2 than the related KIR3DL1 in both healthy controls and
spondyloarthritis (SpA) patients (Chan et al., 2005). CD28−CD4
T cells have been implicated in the pathogenesis of both rheuma-
toid arthritis and SpA (Warrington et al., 2001; Chan et al., 2005;
Raffeiner et al., 2005).
Promoter hypomethylation and an active histone signature
in KIR-expressing cells are associated with KIR3DL2 gene tran-
scriptional activity but factors which speciﬁcally control expres-
sion are unclear (Chan et al., 2003; Santourlidis et al., 2008; Zhang
et al., 2011).
HLA CLASS 1 LIGANDS FOR KIR3DL2
NKAT4 or KIR3DL2*001 was originally shown to bind speciﬁcally
to HLA-A3 and -A11 but not -A1, -A2, and -A24 (Wagtmann
et al., 1995; Dohring et al., 1996; Pende et al., 1996). It was
later shown that KIR3DL2*001 binding to tetramerized peptide
MHC (pMHC) complexes of HLA-A3 and -A11 was critically
dependent on the sequence of complexed viral peptide, with the
RLRAEAQVK EBV/EBNA3A (603–611) epitope promoting inter-
action (Hansasuta et al., 2004). As with other KIR-HLA class 1
interactions positions 7 and 8 of complexed peptide were shown
to be critical for promoting pMHC complex HLA-A3 and -A11
binding to KIR3DL2. The exact role of bound peptide in pMHC
complex recognition by three domain KIRs remains unclear. KIR
binding to class 1 distinguishes self from lack of self asmay happen
when class 1 is down-regulated by virus infection.
Studies on interactions of two domain KIRs with pMHC have
shown that KIR-expressing NK cells respond more readily to
changes in peptide than to changes in HLA class 1 expression
(Fadda et al., 2010). Tumors and viruses do not always necessarily
down-regulate HLA class 1 substantially but may change peptide
repertoire. Under these circumstances peptide selectivity confers
NK cells with an additional recognition mechanism. KIR inhibi-
tion of NK function by pMHC is highly sensitive to the presence of
antagonist peptides which do not induce inhibition (Fadda et al.,
2010). The effect of antagonist peptides in uncouplingKIR cluster-
ing from NK inhibition dominates over effects of agonist peptides
which promote inhibition. This could enable NK cells to discrimi-
nate and respond to small changes in peptide repertoire bound by
HLA class 1 at the cell surface during infection.
In NK development strong class 1 ligands for KIR promote
or “license” NK cells with better effector function. Most of the
identiﬁed peptides which promote binding to three domain KIRs
are from pathogens and few self peptides which promote strong
binding have been identiﬁed (Kollnberger et al., 2007). KIR3DL2-
expressing NK cells in HLA-A3+ individuals have poor effector
function against target cells (Fauriat et al., 2008). This suggests
that it is unlikely that self peptides which promote binding of
pMHC complexes of HLA-A3 to KIR3DL2 are naturally more
abundant.
Residues in theD1 domain of KIR3DL2 are probably critical for
recognition of HLA-A11 and -A3 since gene conversion has gener-
ated KIR2DS4 which binds HLA-A11 but has reduced speciﬁcity
for HLA-C (Graef et al., 2009).
HLA-B27 (B27) is expressed at the cell surface of antigen pre-
senting cells (APCs) as both β2m-associated and free heavy chain
(FHC) species (Kollnberger et al., 2002, Payeli et al., 2012; Bird
et al., 2003). B27 has a reactive cysteine at position 67 which results
in an increased propensity to form FHC species including dimers
at the cell surface. We have shown that KIR3DL2 binds to B27
FHC forms including dimers (Kollnberger et al., 2002). In trans-
fected cells, cell surface B27 heavy chain dimers and other FHC
species form from recycling β2m-associated B27 in an endoso-
mal compartment (Bird et al., 2003). Formation of B27 FHC is
increased when β2m-associated B27 is suboptimally loaded with
peptide (Bird et al., 2003). The extent to which pMHC stabil-
ity and recycling contribute to formation of B27 FHC species in
vivo is unknown. B27 heavy chain dimer tetramers but not β2m-
associated B27 tetramers bind to KIR3DL2 (Kollnberger et al.,
2002, 2007). By contrast, both B27 heavy chain dimers and β2m-
associated B27 bind to KIR3DL1 (Kollnberger et al., 2002, 2007).
KIR3DL2 ligation by B27 FHC inhibits leukocyte production of
IFNγ and promotes NK and T cell survival (Chan et al., 2005;
Bowness et al., 2011). Moreover B27 FHC stimulate IL2 produc-
tion by KIR3DL2CD3ε-transduced Jurkat reporter T cells (Payeli
et al., 2012). KIR3DL2 interaction with HLA-B27 FHC forms is
inhibited by B27-dimer speciﬁc antibodies (Payeli et al., 2012). By
contrast with KIR binding to classical HLA class 1 which depends
on the sequence of complexed peptide, KIR3DL2 binding to B27
heavy chain forms is independent of the sequence of bound pep-
tide (Kollnberger et al., 2007). By contrast, it is unclear whether
B27 FHC interact functionally with KIR3DL1.
It is unknown whether KIR3DL2 interacts functionally with
ligand as a dimer or monomer. Since there is no polymorphic
variation in this region it is plausible that dimerization is impor-
tant for receptor function. The inhibition of KIR3DL2 interaction
with HLA-B27 by the heavy chain-speciﬁc MAb HC10 suggests
that this particular KIR may recognize common shared features
of HLA class 1 heavy chains (Kollnberger et al., 2007). KIR3DL2
dimerization could increase the avidity of interaction with B27
heavy chains. KIR3DL1 binds more strongly to β2m-associated
HLA-B27 tetramers than B27 dimer tetramers (Kollnberger et al.,
2007). Weaker interaction of KIR3DL1 with B27 FHC compared
to KIR3DL2 could offer one possible explanation for why there
is no clear association of KIR3DL1 with SpA. KIR3DL1 has also
been shown to bind to common shared features of HLA class 1.
The recent structure of KIR3DL1 in complex with HLA-B57 sug-
gests that the D0 domain may bind to more conserved regions of
HLA class 1 whereas the D1 and D2 domains provide allelic and
peptide-speciﬁc contacts (Vivian et al., 2011). The D0 domain acts
to enhanceKIR3DL1*001 binding toHLA class 1. Phe9, Trp13,His
29, Phe34 amino acids in the D0 domain of KIR3DL1*001 bind
loops formed by amino acids 14–18 and 88–92 of HLA-B*5701.
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These loops are highly conserved between different HLA class 1
alleles. By analogy the D0 domain of KIR3DL2 could have a role
to play in recognition of HLA-B27 and other HLA class 1 heavy
chains. Notably in KIR3DL2 the D0Trp13 is substituted by a his-
tidine. The relative contributions of these and other residues to
binding of KIR3DL2 to B27 FHC forms and other HLA class 1
remain to be determined.
We propose that multimeric forms of B27 heavy chains which
include B27 dimers interact more strongly with KIR3DL2 and
other immune receptors than other HLA class 1. We have shown
that multimeric FHC forms and heavy chain dimers of B27 bind
more strongly to the leukocyte immunoglobulin-like receptor
LILRB2 than β2m-associated HLA-B27 and other HLA class 1
(Giles et al., 2012). Stronger anti-apoptotic and functional effects
resulting from B27 FHC forms binding to KIR3DL2 compared
with other HLA class 1 ligands could explain why HLA-B27 and
not other HLA class 1 is associated with SpA.
KIR3DL2 FUNCTION
Although KIR3DL2 ligation on NK cells inhibits IFNγ and cyto-
toxic function, its effects on T cell function are less clear. KIR3DL2
ligation inhibits target cell lysis by the TALL104 cell line (Brando
et al., 2005). However, both antibody and HLA class 1 ligation
of KIR3DL2 have been reported to have no effect on CD8 T cell
cytokine secretion and cytotoxicity under certain circumstances
(Pende et al., 1996). This is consistent with the notion that func-
tional effects of KIR onT cells are dependent on the differentiation
and/or activation status of cells expressing these receptors. The
contribution of allelic variation to KIR3DL2 recognition of differ-
ent HLA class 1 is unknown. In addition nothing is known about
the effect of allelic variation on antibody recognition of KIR3DL2.
The large number of protein-encoding polymorphic variants of
KIR3DL2 suggests that the list of class 1 ligands for this receptor
is by no means exhaustive.
INNATE LIGANDS FOR KIR3DL2
Natural killer cells express a range of toll-like receptors includ-
ing TLR3 and TLR9 and are rapidly activated by TLR binding to
PAMPs (reviewed in Marcenaro et al., 2011). Binding of poly I:C
and CpG-oligodeoxynucleotide (ODN) PAMPs to their respec-
tive TLR, TLR-3 and -9 both promotes NK cytokine release and
increases cytotoxicity. Cell surface KIR3DL2 is down-modulated
by binding to CpG-ODN and subsequently KIR3DL2 transports
bound CpG-ODN to endosomes where TLR9 is ligated (Sivori
et al., 2010). KIR3DL2 and KIR3DL1 bind to CpG-ODN via their
D0 domain. Although both KIR3DL1 and KIR3DL2 bind in this
way, KIR3DL2 modulation is particularly strong upon cell expo-
sure to CpG-ODN and KIR3DL2-expressing NK Cells are more
responsive to TLR9-mediated activation. This selective effect of
CpG-ODN on KIR3DL2 could be related to dimerization of the
molecule and/or differences in the cytoplasmic tail compared to
the other three domain KIRs.
KIR3DL2 EXPRESSION IN DISEASE
THE ROLE OF KIR3DL2 IN SPONDYLOARTHRITIS
HLA-B27 is strongly associated with a group of inﬂammatory
arthritides collectively known as the spondyloarthritides/SpA
(Brown et al., 1996). These disorders, characterized by primary
inﬂammation of the sacroiliac joint, include reactive arthritis,
early onset enthesitis related arthritis (ERA),psoriatic arthritis and
IBD-associated enteropathic arthritis and are typiﬁed by ankylos-
ing spondylitis (AS). GWAS studies have identiﬁed genes involved
in regulation of IL17 production including the transcription fac-
tor STAT3 and the IL23 receptor (IL23R) as having important
roles in AS (Reveille et al., 2011). IL17 plays an important role in
diverse autoimmune disorders including rheumatoid arthritis and
SpA (Wendling et al., 2007; Shen et al., 2009; Bowness et al., 2011).
IL17 has multiple proinﬂammatory actions which include stimu-
lating TNFα production and enhancing the recruitment of other
proinﬂammatory leukocytes including neutrophils to the sites of
inﬂammation (Jovanovic et al., 1998; Laan et al., 1999).
We observe increased proportions of NK and CD4 T cells
expressing KIR3DL2 in the peripheral blood and peripheral joints
of patients with SpA (Chan et al., 2005; Bowness et al., 2011).
Patients with B27+ juvenile ERA demonstrated increased pro-
portions of CD4 T cells but not NK cells expressing KIR3DL2
compared to B27 negative healthy and disease controls. By con-
trast, patients with established AS had greater proportions of
both NK and CD4 T cells expressing KIR3DL2 compared to
B27 negative controls. This suggests that KIR3DL2 expression
by CD4 T cells may have a role in initial inﬂammation in B27-
associated arthritis. By contrast, KIR3DL2-expressing NK cell
subsets may be involved in perpetuating inﬂammation. This is
also supported by our observations of greater proportions of
KIR3DL2-expressing CD4 T cells in patients with B27+ reactive
arthritis compared to patientswithmore established disease (Bow-
ness et al., 2011). KIR3DL2+ NK cells from patients expressed
high levels of perforin and the CD38 activation marker and
were enriched for expression of the β7 integrin suggesting a
mucosal and possibly gut origin (Chan et al., 2005). More-
over NK cells from patients were more cytotoxic toward targets
than cells from controls (Chan et al., 2005). However, the rel-
ative contribution of KIR3DL2-expressing and NK cells lacking
KIR3DL2 expression to the increased cytotoxicity was not deter-
mined. NK cells stimulate chemokine and MMP production by
ﬁbroblasts and are themselves sources of chemokines-like IL8
(Raffeiner et al., 2005; Chan et al., 2008; Fauriat et al., 2010). Apart
from increased cytotoxicity it is also possible that KIR3DL2+
expressing NK cell subsets in B27+ SpA patients enhance inﬂam-
mation through activation of key coordinating cells such as
ﬁbroblasts.
We and other authors have also shown increased expression
of HLA class 1 heavy chains and B27 heavy chain dimers on the
surface of B27+ AS patient leukocytes (Kollnberger et al., 2002;
Payeli et al., 2012; Tsai et al., 2002; Raine et al., 2006). We pro-
pose that expansion of KIR3DL2-expressing NK and CD4 T cells
in AS patients is driven by higher avidity interactions with B27
FHCs formed in disease. Stronger interactions with KIR3DL2
could result either from B27 FHC forms binding more strongly
or higher levels of expression of B27 ligands compared to other
HLA class 1.
Increased expression of HC10-reactive heavy chains has also
been associated with psoriatic arthritis (Lan et al., 2004). Notably
both B27+ and B27− psoriatic arthritis patients demonstrated
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increased expression of heavy chains on peripheral blood mono-
cytes compared to controls, with B27− patients showing signiﬁ-
cantly higher levels of expression compared to B27+ (Lan et al.,
2004). Although this hypothesis is attractive, direct evidence for
the physiological relevance of KIR interactions with B27 and
other HLA class 1 heavy chains in vivo remains to be determined.
If KIR3DL2-expressing leukocytes are also involved in psoriatic
arthritis, it is possible that interactions with other class 1 heavy
chains could have a similar effect to B27 in promoting the survival
and differentiation of inﬂammatory leukocytes in these disorders.
KIR3DL2-expressing CD4 T cells are enriched for expression
of Th17 phenotypic markers and particularly IL23R expression
(Bowness et al., 2011). Notably, although comprising just 15%
of all peripheral blood CD4 T cells in SpA, KIR3DL2+CD4
T accounted for 60% of all IL23R-expressing CD4 T cells.
KIR3DL2-expressing CD4 T cells are also enriched for IL23R
expression in healthy B27-controls where they constituted 30%
of all IL23R-expressing CD4 T cells. Moreover, KIR3DL2+CD4 T
cells accounted for the majority of the increase in IL17 produc-
tion by peripheral blood CD4 T cells in SpA patients compared to
healthy and disease controls (Bowness et al., 2011).
The greater expression of KIR3DL2 on CD4 T cells compared
to other KIR allowed us to directly FACS sort this population from
peripheral blood and measure cytokine production by short term
cultures stimulated with anti-CD3, anti-CD28, and anti-CD2.
KIR3DL2 CD4 T cells from SpA patients consistently produced
more IL17 than the same subset isolated from controls. IL17 pro-
duction byKIR3DL2CD4T cell subsets frompatients and controls
was further promoted by stimulation in the presence of the Th17
cytokines IL23 and IL1 (Bowness et al., 2011). However, stimu-
lation with Th17 cytokines promoted a greater increase in IL17
production by the KIR3DL2 CD4 T cell subset from SpA patients
compared to increases in IL17 production by the same subset in
controls.
The observation of production of IL17 by KIR-expressing CD4
T cells contradicts previous observations where KIR-expressing
CD4 T cells were shown to produce only small levels of Th17
cytokines (van Bergen et al., 2004). It is possible that previous
work with KIR-expressing CD4 T cell lines and clones selected for
outgrowth of Th1 cells and IL17 producing cells could have been
missed.
We did not observe signiﬁcant increases in IL23R expression
on CD4 T cells from SpA patients lacking KIR3DL2 expres-
sion (Bowness et al., 2011). We consistently observe expansion
of KIR3DL2-expressing CD4 T cells in B27+ SpA patients and
B27+ but not B27-healthy controls. The increase in KIR3DL2
expression on CD4 T cells in the peripheral blood of B27+ healthy
controls is intermediate between healthy B27− controls and B27+
SpA patients (Bowness et al., 2011). This strongly suggests that
B27 interactions with KIR3DL2 have a central role to play in SpA.
KIR3DL2 interactions with B27 could also have a role to play in
other diseases where HLA-B27 has been shown to play a role. In
addition, the level of surface expression of HLA-B27 may have
a key role in determining progression toward arthritis. Indeed
increased levels of both β2m-associated and FHC forms of B27
have been associated with disease (Cauli et al., 2002; Tsai et al.,
2002; Raine et al., 2006).
We have shown that cell lines expressing HLA-B27 FHC pro-
mote the survival of KIR3DL2CD4T cells secreting IL17 (Bowness
et al., 2011). The Th1 cytokine IFNγ negatively regulates IL17 pro-
duction both by directly inhibiting Th17 cell production and also
inhibiting IL23 production by APCs (Mills, 2008; Sheikh et al.,
2010). In addition to promoting leukocyte survival, KIR3DL2
ligation by B27 could also promote disease by limiting produc-
tion of Th1 cytokines, thus skewing leukocytes toward production
of IL17. If B27 FHC are indeed stronger ligands for KIR3DL2
than other β2m-associated HLAclass 1, stronger binding of B27 to
KIR3DL2 could have a more pronounced effect on inhibition of
IFNγ production than other HLA class 1.
KIR3DL2 ligation by B27 also promotes the survival of NK
cells and inhibits their production of IFN-γ (Chan et al., 2005).
B27 interactions with KIR3DL2 could thus have a role in promot-
ing the expansion of the increased proportions of KIR3DL2+ NK
cells observed in B27+ patients with SpA. The demonstration of
a functional interaction between KIR3DL2 and HLA-B27 raises
the possibility that this interaction could be involved in the devel-
opment of NK effector function or licensing in SpA and other
diseases with B27 involvement.
No speciﬁc alleles of KIR3DL2 have been associated with SpA
(Harvey et al., 2009). These studies do not exclude the possibility
that a rare allelic variant of KIR3DL2 is associated with disease.
We found a similar effect of B27-expressing APC in promoting the
survival of KIR3DL2-expressing CD4 T cells from a wide range of
control and SpA subjects. This suggests that KIR3DL2 polymor-
phism has little effect on the interaction with B27 FHC, although
KIR3DL2 allelic variation could affect the strength of interaction.
THE ROLE OF KIR3DL2 IN SÉZARY’S SYNDROME
Apart from SpA, KIR3DL2 expression delineates both circulating
and inﬁltrating T cell lymphoma cells in Sézary’s syndrome (SS;
Musette et al., 2003; Poszepczynska-Guigne et al., 2004). SS is not
associated with HLA-B27 and the ligand/ligands for KIR3DL2 in
this disease are unknown. SS is an erythrodermic, aggressive, cuta-
neous T-cell lymphoma characterized by a malignant T-cell clone
that localizes in thebloodand skin. Expansionof SSTcells couldbe
driven by innate ligands such as bacterial CpG DNA, or KIR3DL2
expression could occur as a secondary consequence of T cell trans-
formation. The demonstration of expansions of non-lymphoma
T cells expressing KIR3DL2 in SS patients suggests that the latter
possibility is unlikely. SS T cells and KIR3DL2-expressing CD4 T
cells in SS patients have a restricted Vβ TCR repertoire suggest-
ing antigen-driven expansion of these cells (Ortonne et al., 2006).
KIR3DL2 expression has been proposed to be induced on SS T
cells by bacterial exposure. KIR3DL2 expression has also been
reported to be up-regulated on T cells in adult T cell leukemia
which is strongly associated with HTLV-1 infection and associated
infective dermatitis (Obama et al., 2007).
T cells from patients with SS demonstrate constitutive phos-
phorylation of pSTAT3 and secrete IL17 (Ciree et al., 2004; van der
Fits et al., 2012). KIR3DL2 ligation by an as yet uncharacterized
ligand may promote expansion of T cells in SS. Candidate ligands
could be CpG DNA or HLA class 1 heavy chains. Alternatively,
increased KIR3DL2 expression could result from T cell activation
independently of binding to ligand. SS T cells may also have a
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FIGURE 1 | Hypothetical role of KIR3DL2 ligand interactions in
inflammation. KIR3DL2 is expressed as a disulphide-bonded dimer with D0,
D1, D2 immunoglobulin-like domain organization and two cytoplasmic ITIM
motifs. (1) KIR3DL2 expression is induced byT cell activation and/or NK
differentiation. (2) Bacterial infection may promote formation of B27 dimers
(B272) and free heavy chains (FHC) by enhanced recycling of β2m-associated
HLA class 1 by antigen presenting cells (APC). (3) B27 FHC including B272
could bind more strongly to KIR3DL2 than β2m-associated HLA class 1. B27
FHC are predicted to bind to KIR3DL2 via the D0 domain. (4) KIR3DL2 binding
to ligand inhibits activation induced cell death driven byTCR/NK receptor
ligand interactions, promoting the survival of pathogenic Th17 and NK cell
subsets in disease. The D0 domain of KIR3DL2 also binds bacterial CpG DNA.
CpG DNA internalized by KIR3DL2 could costimulate NK andT cell via TLR9
ligation (1 and 4).
role in neutrophil recruitment to inﬂammatory sites in the skin in
SS as neutrophil recruitment correlates with IL17 production by
these cells. Although IL17 itself is not essential, IL21 produced by
SS T cells has an important role to play in the maintenance of this
subset (van der Fits et al., 2012).
KIR3DL2 CD4 T cells in SpA have a highly activated pheno-
type suggesting that expression may be induced by chronic T cell
activation (Chan et al., 2005). B27+ reactive arthritis is associated
with gram-negative intracellular bacterial infection. Evidence of
subclinical gut inﬂammation in SpA patients and the association
of HLA-B27 with inﬂammatory bowel disease also link SpA with
bacterial infection (Ciccia et al., 2009; Brown, 2011). One possibil-
ity is that KIR3DL2 expression in SpA and SS is linked to bacterial
activation of leukocytes.
CONCLUDING REMARKS
KIR3DL2 is a highly polymorphic framework KIR gene. Figure 1
summarizes how KIR3DL2 expression and ligation may con-
tribute to immune regulation and inﬂammation. Differences in
potential transcription binding sites between KIR3DL2 and other
KIR genes and the large size of the KIR3DL2 gene locus sug-
gest unique transcriptional control. KIR3DL2 ligands include
HLA-A3 and -A11, HLA-B27 FHC dimers and other FHCs and
CpG-ODN. The inﬂuence of KIR3DL2 dimerization on ligand
binding remains to be determined. KIR3DL2 expression is up-
regulated on activated CD4 T cells and NK cells in SpA and
circulating and T cell lymphoma cells in SS. Since both disor-
ders are associated with bacterial infection, it is possible that
bacterial exposure in general may have a role in promoting
the expansion of KIR3DL2-expressing T cells. The enrichment
of expression of Th17 phenotypic markers and production of
IL17 by peripheral KIR3DL2-expressing CD4 T cells suggests a
unique role for KIR3DL2 expression in the differentiation of
Th17 cells.
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